DIAGNOSTIC_TEST
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit
Status
Completed
Phase
Not applicable
Enrollment
241
Locations
1
Results
Not posted
Publications
5
Study summary
The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) as a cardiac biomarker in predicting short-term major adverse cardiovascular events (MACEs) in patients with Acute coronary syndrome (ACS) has been insufficiently reported and remains poorly understood. Additionally, the relationship between NT-proBNP levels and specific ACS subtypes has not been thoroughly examined. Therefore, our study investigated the predictive value of high-sensitivity cardiac troponin (hs-cTn) and NT-proBNP levels on admission for 6-month MACEs in patients who presented to the emergency department (ED) with ACS and subsequently underwent percutaneous coronary intervention (PCI). Furthermore, we sought to evaluate the association between MACEs and specific ACS subtypes.
In patients diagnosed with Acute coronary syndrome (ACS) based on anamnesis, clinical findings, electrocardiogram (ECG), and/or serum high-sensitivity cardiac troponin (hs-cTn) level in the emergency department (ED), blood samples for serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) value was additionally taken during transfer to the coronary intensive care unit, and left ventricular ejection fraction (LVEF) was calculated by echocardiography before percutaneous coronary intervention (PCI). In addition, demographics (age, sex, and smoking status), comorbidities (hypertension, diabetes mellitus \[DM\] and/or coronary artery disease \[CAD\]), initial complaints and diagnoses, vital signs (systolic blood pressure \[SBP\], heart rate \[HR\], and peripheral capillary oxygen saturation \[SpO2\]), laboratory parameters (serum creatinine, C-reactive protein, and hs-cTn), and ACS subtypes (ST-elevation Myocardial infarction \[STEMI\], non-ST-elevation Myocardial infarction \[NSTEMI\], or unstable angina pectoris \[USAP\]) were obtained during admission. GRACE risk score was calculated for each patient on admission using eight variables, including age, SBP, HR, and serum creatinine. At the end of the 6-month follow-up period, LVEF of surviving patients was assessed by control echocardiography. The short-term MACEs (e.g., nonfatal ischemic stroke, nonfatal myocardial infarction, cardiovascular mortality, or ED admission due to heart failure) were recorded.
Interventions
DIAGNOSTIC_TEST
In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit
DIAGNOSTIC_TEST
In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.
Timeline
First posted
Aug 26, 2024
Study start
Sep 1, 2023
Primary completion
Feb 1, 2024
Study completion
Mar 1, 2024
Results posted
Not reported
Registry updated
Aug 26, 2024
Outcomes
Predictive ability of NT-proBNP for 6-months MACEs
Time frame · From admission to 6 months
The investigators assessed the effectiveness of N-terminal pro-B-type natriuretic peptide (NT-proBNP) value at admission in predicting 6-months major adverse cardiovascular events (MACEs) in patients with acute coronary syndrome.
Incidence of MACEs in STEMI
Time frame · From admission to 6 months
The investigators assessed the incidence of major adverse cardiovascular events (MACEs) in patients with ST-elevation myocardial infarction (STEMI).
Incidence of MACEs in NSTEMI
Time frame · From admission to 6 months
The investigators assessed the incidence of major adverse cardiovascular events (MACEs) in patients with non-ST-elevation myocardial infarction (NSTEMI).
Incidence of MACEs in USAP
Time frame · From admission to 6 months
The investigators assessed the incidence of major adverse cardiovascular events (MACEs) in patients with unstable angina pectoris (USAP).
Eligibility
Inclusion Criteria: * Adult patients (≥18 years old) who were admitted to the emergency department with Acute coronary syndrome and underwent percutaneous coronary intervention between September 2023 and February 2024. Exclusion Criteria: * patients younger than 18 years * patients had no vascular lesions detected on percutaneous coronary intervention, * patients had infective or structural cardiac pathologies (myocarditis, pericarditis, hypertrophic or dilated cardiomyopathies) * patients had chronic heart failure with LVEF \<40%, class 3 and 4 in the Killip classification * patients had a diagnosis of malignancy, chronic renal failure, chronic liver failure, and a history of multiple trauma or surgery within the last month
Study locations
Turkey (Türkiye). Showing up to 24 locations stored in the fast local snapshot.
Haseki Training and Research Hospital
Istanbul, Fatih, Turkey (Türkiye)
Publications
Related trials
Universidade do Porto · Heart Failure
Not applicable
Recruiting
160
2026-07
Boston Medical Center · Congestive Heart Failure · Volume Overload
Not applicable
Not yet recruiting
200
2026-06
Norfolk and Norwich University Hospitals NHS Foundation Trust · Vascular Surgical Procedure
Not applicable
Recruiting
200
2026-06
China National Center for Cardiovascular Diseases · AKI - Acute Kidney Injury · Cardiac Surgical Procedures
Phase 4
Not yet recruiting
694
2026-06
Cambridge University Hospitals NHS Foundation Trust · Heart Failure
Not applicable
Recruiting
250
2026-05
Chulalongkorn University · Acute Kidney Failure Stage 3
Not applicable
Completed
100
2026-05
Ottawa Heart Institute Research Corporation · Chronic Right-Sided Heart Failure · Pulmonary Arterial Hypertension
Phase 4
Completed
15
2026-05
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.